Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: Long-term results

Frédéric Maloisel*, Emmanuel Andrès, Jacques Zimmer, Esther Noel, Alina Zamfir, Argyro Koumarianou, Patrick Dufour

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

90 Citations (Scopus)

Abstract

Background Adults with chronic idiopathic thrombocytopenic purpura (ITP) in whom standard-dose corticosteroids and splenectomy have failed or who have contraindications to these therapies often require further treatment for life-threatening thrombocytopenia or bleeding. We studied whether danazol, an attenuated androgen, is useful in this setting. Methods To assess both clinical outcome and tolerance issues, 57 patients who had refractory chronic ITP (n = 27) or who had contraindications to splenectomy or corticosteroids or who refused these therapeutic options (n = 30) were studied. Results Thirty-eight patients experienced a partial or complete response to therapy (67%), among whom 27 (46%) remained in remission at a median (± SD) of 119 ± 45 months. Treatment tolerance was acceptable, although severe adverse events were reported in 9 patients (16%). Conclusion Our findings suggest that danazol therapy may be beneficial in the management of refractory chronic ITP or when there are contraindications to splenectomy or corticosteroids (or both).

Original languageEnglish
Pages (from-to)590-594
Number of pages5
JournalAmerican Journal of Medicine
Volume116
Issue number9
DOIs
Publication statusPublished - 1 May 2004
Externally publishedYes

Fingerprint

Dive into the research topics of 'Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: Long-term results'. Together they form a unique fingerprint.

Cite this